Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 02 Feb 2023

Effects of plasma-derived exosomes from the normal and thin Bactrian camels on hepatocellular carcinoma and their differences at transcriptome and proteomics levels

in Cancer Molecular Targets and Therapeutics

Hongqiang Yao
Siriguleng Yu
Yuchen Luo
Ming Wang
Xiuying Wang
Siriguleng Xu
Yufei Chen
Zhifeng Xie

Frontiers in Oncology

doi 10.3389/fonc.2023.994340

2,236 views
1 citation

Mini Review

Published on 01 Feb 2023

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

in Cancer Molecular Targets and Therapeutics

Liza C. Villaruz
Mark A. Socinski
Jared Weiss

Frontiers in Oncology

doi 10.3389/fonc.2023.1124167

8,232 views
17 citations

Original Research

Published on 01 Feb 2023

Autolysosomal activation combined with lysosomal destabilization efficiently targets myeloid leukemia cells for cell death

in Cancer Molecular Targets and Therapeutics

Harshit Shah
Metodi Stankov
Diana Panayotova-Dimitrova
Amir Yazdi
Ramachandramouli Budida
Jan-Henning Klusmann
Georg M. N. Behrens

Frontiers in Oncology

doi 10.3389/fonc.2023.999738

2,105 views
2 citations

Editorial

Published on 31 Jan 2023

Editorial: Targeting redox regulation and autophagy systems for cancer therapy

in Cancer Molecular Targets and Therapeutics

Junmin Zhang
Abdelhabib Semlali
Paola Maycotte
Luciano Saso

Frontiers in Oncology

doi 10.3389/fonc.2023.1146670

1,504 views

Original Research

Published on 30 Jan 2023

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Shuai Han
Dongjie Jiang
Feng Zhang
Kun Li
Kun Jiao
Jingyun Hu
Haihan Song
Qin-Yun Ma
Jian Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1095313

3,398 views
5 citations

Original Research

Published on 27 Jan 2023

Identification of thioredoxin-1 as a biomarker of lung cancer and evaluation of its prognostic value based on bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Xiaoting Liu
Xilin Dong
Yaxin Hu
Yanan Fang

Frontiers in Oncology

doi 10.3389/fonc.2023.1080237

2,833 views
6 citations

Review

Published on 26 Jan 2023

Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy

in Cancer Molecular Targets and Therapeutics

Ananna Bhadra Arna
Hardikkumar Patel
Ravi Shankar Singh
Frederick S. Vizeacoumar
Anthony Kusalik
Andrew Freywald
Franco J. Vizeacoumar
Yuliang Wu

Frontiers in Oncology

doi 10.3389/fonc.2022.1087989

6,190 views
4 citations

Original Research

Published on 26 Jan 2023

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients

in Cancer Molecular Targets and Therapeutics

Hui Zhang
Yi Hu
Yan Wang
Xia Song
Ying Hu
Li Ma
Xinjie Yang
Kun Li
Na Qin
Jinghui Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.942123

3,257 views
7 citations

Original Research

Published on 26 Jan 2023

HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development

in Cancer Molecular Targets and Therapeutics

Yue Huang
Zhiwei Rong
Liuchao Zhang
Zhenyi Xu
Jianxin Ji
Jia He
Weisha Liu
Yan Hou
Kang Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1047556

1,936 views
1 citation

Original Research

Published on 26 Jan 2023

SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration

in Cancer Molecular Targets and Therapeutics

Katja Eloranta
Marjut Pihlajoki
Emmi Liljeström
Ruth Nousiainen
Tea Soini
Jouko Lohi
Stefano Cairo
David B. Wilson
Seppo Parkkila
Markku Heikinheimo

Frontiers in Oncology

doi 10.3389/fonc.2023.1118268

6,365 views
18 citations

Review

Published on 25 Jan 2023

Krüppel-like factors in tumors: Key regulators and therapeutic avenues

in Cancer Molecular Targets and Therapeutics

Yuchen Zhang
Chongjie Yao
Ziyong Ju
Danli Jiao
Dan Hu
Li Qi
Shimin Liu
Xueqing Wu
Chen Zhao

Frontiers in Oncology

doi 10.3389/fonc.2023.1080720

5,624 views
16 citations

Original Research

Published on 23 Jan 2023

GPBAR1 is associated with asynchronous bone metastasis and poor prognosis of hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Nan Chen
Jieqing Wang
Lei Zhou
Baiqiang Hu
Yinzhong Chen
Zhuangchen Zhu

Frontiers in Oncology

doi 10.3389/fonc.2022.1113785

1,974 views
3 citations

Review

Published on 23 Jan 2023

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade

in Cancer Molecular Targets and Therapeutics

Deborah Choe
Dongwon Choi

Frontiers in Oncology

doi 10.3389/fonc.2023.1088038

7,473 views
14 citations

Review

Published on 23 Jan 2023

COMMD proteins function and their regulating roles in tumors

in Cancer Molecular Targets and Therapeutics

Guangqiang You
Chen Zhou
Lei Wang
Zefeng Liu
He Fang
Xiaoxao Yao
Xuewen Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1067234

9,969 views
6 citations

Review

Published on 23 Jan 2023

Sulforaphane: An emergent anti-cancer stem cell agent

in Cancer Molecular Targets and Therapeutics

Leandro de Lima Coutinho
Tharcísio Citrangulo Tortelli Junior
Maria Cristina Rangel

Frontiers in Oncology

doi 10.3389/fonc.2023.1089115

27,932 views
26 citations

Original Research

Published on 20 Jan 2023

HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line

in Cancer Molecular Targets and Therapeutics

Jens von den Driesch
Jana Flöttmann
Friedrich Prall
Christina S. Mullins
Michael Linnebacher
Florian Bürtin

Frontiers in Oncology

doi 10.3389/fonc.2022.1082927

2,501 views
3 citations